• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai , Oct 26

THE Mumbai-based Nicholas Piramal India Ltd (NPIL) has signed a development and know-how agreement with Sweden's AstraZeneca AB for drug-intermediates.

No details were disclosed on the deal size or the segments covered.

As per the agreement with AstraZeneca, the companies will collaborate on the development of processes and the manufacture of intermediates, active ingredients or bulk drugs for supply to AstraZeneca.

The agreement does not have a fixed tenure.

It is envisaged to last so long as the parties have products under development, NPIL told the Bombay Stock Exchange.

If the collaboration on any of the products developed is successful, the agreement allows the parties to further negotiate terms for supply of the product by NPIL to AstraZeneca.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Jones Lang LaSalle plans to increase headcount

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line